SillaJen신라젠

SillaJen posts deep operating losses on minimal revenue, with trial news at ESMO the main recent development.

SillaJen, a Seoul-listed cancer drug developer founded in 2006, reported trailing twelve-month revenue of about ₩10.8B against an operating loss of about ₩26.1B as of H1 2026. Its market value is about ₩295B at a close of ₩2,130, down 30% over the past year and well below its 52-week high of ₩5,400. Recent attention centres on interim results for its BAL0891 candidate presented at the European Society for Medical Oncology.

What stands out

• Trailing revenue of about ₩10.8B is far below the operating loss of about ₩26.1B, giving an operating margin of roughly -243%.
• Cash of about ₩6.0B and no borrowings, but trailing free cash flow of about -₩20.6B, so the cash balance covers only a short period at that burn rate.
• Losses have been persistent: operating income was negative in every year from 2021 to 2025, and 2025 revenue rose 135% to about ₩9.2B while the operating loss stayed near ₩25.6B.
• Shares have fallen 30% over one year and 4.9% over one month, but are up 10.1% over three months; foreign ownership fell from 3.8% to 2.8% over the last 60 days.
• Trial updates at ESMO on October 25 and 26 reported a 21.4% response rate in a combination group for BAL0891, with the company citing signs of efficacy; these are interim results.

What to watch

• Upcoming quarterly and annual filings, to see whether revenue growth continues and whether cash burn narrows.
• Whether the company needs new funding, given the gap between cash on hand and trailing free cash flow; the data does not include any financing plan.
• The September 2026 filing titled 'Major management matter relevant to investors' has no detail in the data, so its content is unknown.